


NOW
ARRIVED
10mg Tablet

Return Ticket



- Effective control of symptoms.
- Resocialization and improved social performance.
- Low incidence of E.P.S.

once daily
Orap*
pimozide

to help the schizophrenic patient
regain his place in society.

PRESCRIBING INFORMATION Presentation White, scored, uncoated tablets marked "Janssen" on one side and 0/2 on the other, each contains 2 mg pimozide. Pale green, scored, uncoated tablets marked "Janssen" on one side and 0/4 on the other, each contains 4 mg pimozide. White, scored, uncoated tablets marked "Janssen" on one side and 0/10 on the other, each contains 10 mg pimozide. **Uses** Orap* is an antipsychotic of the diphenyl butyl-piperidine series and is indicated for the treatment of acute or chronic schizophrenia. Hallucinations, delusions, thought disorders and emotional withdrawal respond well to lower doses of the drug. Higher doses may be needed for the control of acutely agitated, hyperactive or aggressive patients. **Dosage and Administration** Orap* is intended for oral administration to both adults and children. Patients may be maintained on a once daily dosage regime. As with all neuroleptics, it is important to determine the dose of Orap* according to the individual response of each patient. **In adults:** Dosage ranges between 2-20 mg daily. The usual initial dose is 4-10 mg, which may be varied according to response and tolerance to achieve an optimum maintenance dosage. In the acutely agitated patient the initial dose is 20 mg. Gradual reduction to the lowest effective maintenance dose may be attempted once control of symptoms is achieved. **In children:** In children over 12 years of age dosage should normally be 1-3 mg daily. Clinical experience in young children is limited and, therefore, Orap* should be used at the physician's discretion in children under 12 years of age. **Contra-indications, warnings, etc.** **Contra-indications:** Although no teratological changes have been observed in experimental animals, the drug should not be administered to pregnant women. **Warnings:** Endogenous depression, pre-existing Parkinson's disease and epilepsy may be aggravated. **Overdosage:** There is no specific antidote to an overdose of pimozide. Cases should be treated symptomatically. A suicide attempt with 100 mg pimozide produced only slight tremor and another with 200 mg showed no specific side-effects and needed no treatment. **Side-effects:** Extra-pyramidal effects may occur at higher dosage levels. Occasional skin rashes have been reported. Glycosuria has been reported following Orap* administration, but it has not been established whether this effect was drug related. **Pharmaceutical precautions Nil.** **Legal category POM.** **Package quantities** Orap* tablets each containing 2 mg pimozide are supplied in packs of 100, 500 and 2,500. Orap* tablets each containing 4 mg pimozide are supplied in a pack of 250. Orap* tablets each containing 10 mg pimozide are supplied in a pack of 100. **Further information Nil.** **Product licence numbers** Orap* 2 mg 0242/5010, Orap* 4 mg 0242/0038, Orap* 10 mg 0242/0069. **Basic N.H.S. Cost** 10p/97p/day (4 mg x 250 pack) depending on dosage (2 mg/20 mg). (Correct at time of printing)

 Further information is available and will gladly be supplied on request
Psychiatric Information Service. Janssen Pharmaceutical Ltd, Janssen House, Chapel Street, Marlow, Bucks, SL71ET Orap* is a trademark

NOTES FOR CONTRIBUTORS

PAPERS Papers for publication should be addressed to the Editor, Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF. Contributors should send at least three copies of the text, tables, and figures. Copies other than the first may be xeroxed. The S.I. system should be adopted for text and figures. A short synopsis of about 50 words should be provided at the beginning of each article. Foreign quotations and phrases should be followed by a translation. Submission of a paper will be held to imply that it contains original work that has not been previously published and that it is not being submitted for publication elsewhere.

In addition to longer articles, the Editor is prepared to accept preliminary communications of between 1500 and 2000 words.

Manuscripts must be typewritten on one side of the paper in double-spacing with wide margins. The following information must be given on a single separate sheet: (1) title and short title for running head (not more than 100 characters); (2) authors' names, and (3) department in which work was done. Footnotes on the same sheet should list: (i) the authors' present addresses if different from departments in which work was done; (ii) name and address of the author to whom correspondence should be addressed; (iii) receipt of grants. Authors who would like a reprint address to be printed should include this on their manuscript.

REFERENCES (1) In the text these should follow the Harvard system – that is, name followed by date: Brown (1970). If there are more than two authors the first author's name followed by *et al.* should be used, even the first time that the reference appears. (2) The list of references should be typed in alphabetical order on a separate sheet and should appear as follows: Brown, J., Williams, E. & Wright, H. (1970). Treatment of heroin addiction. *Psychological Medicine* 1, 134–136. Journal titles should be given in full.

Books should be cited as follows: Brown, J. (1970). *Psychiatric Research*. Smith: Glasgow.

ILLUSTRATIONS Only essential figures and tables should be included. *Photographs* Unmounted photographs on glossy paper should be provided. Magnification scales, if necessary, should be lettered on these. Where possible, prints should be trimmed to column width (i.e. 70 mm). *Diagrams* These will usually be reduced to 70 mm wide. Lettering should be in either Letraset or stencil, and care should be taken that lettering and symbols are of comparable size. Illustrations should not be inserted in the text, they should be marked on the back with figure numbers, title of paper, and name of author. All photographs, graphs, and diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet. *Tables* Tables should be numbered consecutively in the text in Arabic numerals and each typed on a separate sheet.

PROOFS AND OFFPRINTS Page proofs will be sent to the senior author. Corrections other than printer's errors may be charged to the author. Fifty offprints of each paper are supplied free; additional offprints are available according to a scale of charges if they are ordered when the proof is returned.

Psychological Medicine

Volume 11 Number 4 November 1981

CONTENTS

EDITORIALS

Drug assays in neuropsychiatry	page 661
Where have all the catatonics gone?	669
Dementia, depression and the CT scan	673
BERRIOS, G. E. Stupor: a conceptual history	677
KOEHLER, K. G. The Schreber case and affective illness: a research diagnostic re-assessment	689
HALMI, K. A., FALK, J. R. AND SCHWARTZ, E. Binge-eating and vomiting: a survey of a college population	697
FAIRBURN, C. A cognitive behavioural approach to the treatment of bulimia	707
GALDI, J., RIEDER, R. O., SILBER, D. AND BONATO, R. R. Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study	713
VAN PUTTEN, T., MAY, P. R. A. AND JENDEN, D. J. Does a plasma level of chlorpromazine help?	729
ASHTON, J. R. AND DONNAN, S. Suicide by burning as an epidemic phenomenon: an analysis of 82 deaths and inquests in England and Wales in 1978-9	735
RAY, C. AND FITZGIBBON, G. Stress arousal and coping with surgery	741
MCCARTNEY, J. AND Ó'DONNELL, P. J. The perception of drinking roles by recovering problem drinkers	747
DUNN, G. AND SKUSE, D. The natural history of depression in general practice: stochastic models	755
JENKINS, L., TARNOPOLSKY, A. AND HAND, D. Psychiatric admissions and aircraft noise from London Airport: four-year, three-hospitals' study	765
STURT, E. Hierarchical patterns in the distribution of psychiatric symptoms	783
ANDREWS, G. A prospective study of life events and psychological symptoms	795
FINLAY-JONES, R. AND BROWN, G. W. Types of stressful life event and the onset of anxiety and depressive disorders	803
O'MUIRCHARTAIGH, C. A. AND WIGGINS, R. D. The impact of interviewer variability in an epidemiological survey	817
SZMUKLER, G. I. Compulsory admissions in a London borough: II. Circumstances surrounding admission: service implications	825
PRELIMINARY COMMUNICATIONS	
The development and use of a standardized assessment of abnormal personality A. H. MANN, R. JENKINS, J. C. CUTTING AND P. J. COWEN	839
Voice pitch measurements in schizophrenia and depression J. LEFF AND E. ABBERTON	849
Long-term psychotropic drug-taking and the process of withdrawal J. MURRAY	853
BOOK REVIEWS	859
INDEX TO VOLUME 11	873

© Cambridge University Press 1981

CAMBRIDGE UNIVERSITY PRESS

The Pitt Building, Trumpington Street, Cambridge CB2 1RP
32 East 57th Street, New York, N.Y. 10022

Printed in Great Britain at the University Press, Cambridge